Exagen logo_440x386 (1).jpg
Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection
January 09, 2022 12:00 ET | Exagen Inc.
SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a...
visiongain Logo.png
Autoimmune Disease Therapeutics Market Report Up to 2031: Visiongain Research Inc
December 23, 2021 09:00 ET | Visiongain Ltd
Visiongain has published a new report on Autoimmune Disease Therapeutics Market Report to 2031. Market is segmented By Indication (Rheumatic Disease, Multiple Sclerosis, Diabetes, Inflammatory Bowel...
visiongain Logo.png
Animal Autoimmune Disease Diagnostics Market Report Up to 2031: By Visiongain Research Inc
November 16, 2021 06:13 ET | Visiongain Ltd
Visiongain has published a new report on Animal Autoimmune Disease Diagnostics Market Report to 2031: Forecasts By Test Type (Complete Blood Count, Thyroid Test, Biopsy Test, Urinalysis, DNA...
Graphical Research.jpg
Clinical Trial Market Size & Share 2021 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research
November 09, 2021 06:00 ET | Graphical Research
Pune, India, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The global clinical trial market size is estimated to rise exponentially during the forecast period, as the need for advanced vaccines and drugs to...
ZEUS Scientific Acquires Synthetic Peptides from Sheba Medical Center's Tech Transfer Co.
October 29, 2021 08:30 ET | ZEUS Scientific
BRANCHBURG, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- ZEUS Scientific has obtained exclusive, worldwide rights to the use of these synthetic peptides as targets of disease-specific autoantibodies in...
Exagen logo_440x386 (1).jpg
Exagen to Announce Third Quarter 2021 Financial Results on November 10, 2021
October 27, 2021 16:05 ET | Exagen Inc.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2021...
Exagen logo_440x386 (1).jpg
Exagen Inc. Expands Coverage with Inland Empire Health Plan, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE Lupus
October 27, 2021 08:25 ET | Exagen Inc.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE Lupus are a contracted covered...
Exagen logo_440x386 (1).jpg
Exagen Inc. Announces $27.2 Million Debt Refinancing
October 25, 2021 08:25 ET | Exagen Inc.
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security...
Exagen logo_440x386 (1).jpg
Exagen Showcases Eight Scientific Presentations at ACR’s Virtual Annual Meeting in November 2021
October 21, 2021 16:05 ET | Exagen Inc.
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today it will be presenting new scientific research at the...
ScipherTM.png
Trellis Rx Furthers Commitment to Advancing the Specialty Pharmacy Practice and Patient Outcomes with Integration of Scipher Medicine® PrismRA® Precision-Medicine Technology into Clinical Pathways
October 12, 2021 08:00 ET | Scipher Medicine Corporation
ATLANTA and WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Trellis Rx, a leading technology-enabled specialty pharmacy services provider, today announced the integration of PrismRA®, a diagnostic...